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Abstract. Prior to treatment in patients with discirculatory encephalopathy stage II affected by 
hypertensive disease set at the system level elevation of proinflammatory and regulatory 
cytokines, stable metabolites of nitric oxide, a decrease of immunoglobulins M, G, A, disbalance 
of the complement system components, development oxidative stress. Inclusion of a 
comprehensive drug treatment of patients with discirculatory encephalopathy cerebrolysin 
combination with meksidol normalizes the concentration of C3 and C4 components of the 
complement system, IgG, malondialdehyde, catalase activity, total antioxidant activity of blood 
serum, corrects, but not to the level of standards, the contents of cytokines (TNF, IL-1β, IL-6, IL-
8, IL-18, IFγ, IL-2, IL-17), complement component C5, IgA, acylhydrohyperoxide, neopterin and 
increases anti-inflammatory cytokines. Using emoxipine and piracetam as part of 
pharmacotherapy vascular encephalopathy stage II, compared with a combination of cerebrolysin 
and meksidol to further normalize levels of IL-17, C-reactive protein, increasingly closer to that 
of a control group of IL-6, IL-2 IL-18, C5, C5a component of complement, IgM, AGP, SMNO, 
increases the concentration of the complement system and cytokine network controllers. Included 
in the complex pharmacotherapy of patients with discirculatory encephalopathy and a 
combination aktovegin and cereton has maximum efficiency, normalizing 52% and 48% broken 
correlation immune parameters. 
Keywords: immune, oxidant disturbances, discirculatory encephalopathy, cerebrolysin, 
meksidol, emoxipine, piracetam, aktovegin, cereton 
 
Introduction. Modern Angiology is 
characterized by the increasing number of patients 
with cerebrovascular disorders as a result of 
population aging. Along with acute forms of 
cerebrovascular diseases, chronic brain ischemia is 
making a significant contribution to the high 
morbidity and mortality of the population [1, 2]. The 
Russian Ministry of Health Order “On approval of 
the scientific medical science platforms” (№ 281 
dated 30.04.2013) indicated on the high mortality rate 
of working-age persons from diseases of the 
circulatory system, which has a negative impact on 
demographics, medical and social and economic 
development of the country. 
Chronic brain ischemia, also referred as 
encephalopathy, is  a syndrome which  slowly 
progressive brain dysfunction with cognitive and 
other neurological defects, developing as a result of 
diffuse and / or fine-focal brain damage tissue under 
conditions of permanent failure of its blood supply or 
recurrent acute disorders. DEP is a heterogeneous 
syndrome etiopathogenesis, and in its appearance it 
plays a role of immune mechanisms, metabolic 
disorders along with hemorheological defects and 
endothelial dysfunction [3, 4, 5, 6]. 
Encephalopathy which is caused by arterial 
hypertension, activates microgliacyte resulting in the 
induction of a local inflammatory response involving 
cytokines. The important target cells for the last 
astrocytes are involved in decreasing immune 
tolerance of the organism to the brain tissues, 
together with the processes of apoptosis and 
endothelial dysfunction resulting in damage to 
neuronal tissue. Immune inflammation and lipid 
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metabolism lead to irreversible damage to the 
membrane phospholipid complexes and destructive 
processes in the glia, which is one of the reasons for 
the clinical manifestations of DEP [7, 8, 9, 10, 11]. 
It should be appreciated that cytokines, 
complement system and immunoglobulins are the 
most important and versatile functionally group of 
humoral immune status factors involved in mediating 
endothelial functions realizing intercellular 
interactions during hematopoiesis, inflammation, 
immune processes and intersystem communications 
[12, 13]. 
A study on the state of the immune and 
oxidative status and correction of such violations are 
relevant [14, 15, 16]. 
These works provide an opportunity to create 
new methods of early diagnosis and personalized 
treatment approach based on the identified 
neuroendocrine and immune mechanisms of 
cerebrovascular diseases. 
So, the development of pathogenetically 
substantiated pharmacotherapeutic strategy of acute 
and chronic ischemic brain damage is one of the 
urgent problems of modern medicine. 
Research objective is to evaluate the clinical 
and laboratory efficiency combined using drugs with 
nootropic and antioxidant activity in patients with 
discirculatory encephalopathy affected by 
hypertensive disease. 
OWN RESEARCHES 
Clinical impressions. The investigations were 
carried out establishing of the neurological 
department of BMU «Kursk regional clinical 
hospital» at the Department of Neurology and 
Neurosurgery of the Kursk State Medical University. 
In the placebo-uncontrolled survey there were 48 
patients with stage II DEP affected by essential 
hypertensive disease grade 2, stage 2, the risk 2 
(active treatment group) and 12 healthy patients 
(comparison group). The age of patients and 
members of the active treatment group was 50 ± 5 
years. The diagnosis was explained by the results of 
preassessment: 1) the availability of health disorders, 
including cognitive and psycho-emotional spheres;  
2) presence of neurological syndromes - vestibulo-
ataxic syndrome, hereditary cerebellar ataxia, 
pyramid sign, pseudobulbar syndrome; 3) the 
presence of cognitive dysfunction syndrome;  
4) vascular pattern of changes in the brain by MRT in 
the form of leukoaraiosis, lacunar focus inside of 
mild and moderate hydrocephalus. 
Inclusion criteria into the active treatment group: 
female, DEP stage II affected by hypertensive disease 
grade 2, stage 2, the risk is 2, diagnosed 5 or more 
years ago, in accordance with the recommendations 
of the World Health Organization and the 
International Society of Hypertension (WHO/ISH, 
1999), having a regular menstrual cycle, tolerability 
profile, written consent to participate in the research. 
Exclusionary criteria was haemodynamic stenoses of 
the brachiocephalic and cerebral vascular disorders, 
rhythm disturbance of heart function, heart disease, 
myocardial infarction, postinfarction cardiosclerosis 
and cardiac angina or the presence of indications of 
their anamnesis, secondary hypertension, congestive 
heart failure, diabetes or impaired glucose tolerance, 
expressed or moderate atherosclerotic changes in 
retinal vessels, carried over serious head injuries, 
alcoholism, apoplectic attack in past medical history, 
with an estimate of the Khachinsky’s scale less than 7 
points, severe and the most severe condition, somatic 
pathology in the stage of incomplete remission or 
exacerbation, allergic reactions to treatment, refusal 
of treatment. 
Examination technic included a clinical 
evaluation of neurological status, the investigation of 
cognitive functions on a scale «MMSE», the severity 
of cognitive impairment on a scale general 
deterioration – Global Deterioration Rating. To 
confirm the vascular temperament of the DEP and the 
extent of brain damage using MRT (Philips company 
unit, the magnetic field voltage of 1 Tesla). All 
patients were counseled by an ophthalmologist and a 
cardiologist. 
Patients with DEP were accidentally divided 
into three groups of 16 people; they received 10-day 
drug treatment with various combinations of 
nootropic and antioxidant drugs during two weeks of 
comprehensive basic. 
The daily basic pharmacotherapy there were 
included angiotensin-converting enzyme inhibitor 
enalapril (Hemofarm AD, Serbia) to 10 mg per day in 
and ethyl apovincaminic acid (Bravinton, 
vinpocetine, Vintsetin, Cavintonum of «Gedeon 
Richter», Hungary) 25 mg 500.0 ml of a 0.9% NaCl 
solution intravenously. Additional pharmacotherapy 
it was conducted by paired combinations of drugs 
with neurometabolic action with antioxidant and 
antihypoxic effects, daily for 10 days. Their 
application corresponds to the recommendations of 
the Russian management of patients with chronic 
cerebral ischemia and Federal guidelines on using of 
medicines. 
Patients in Group 1 were administered every day 
2152 mg concentrate cerebrolysin (set of peptides 
derived from pig’s brain) (Cere, «EBEWE Pharma 
Ges.mbH Nfg. KG», Austria) intravenously in 100.0 
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ml of 0.9% solution sodium chloride, and 2-ethyl-6-
methyl-3-hydroxypyridine succinate (Mexidol, LLC 
«NPK Pharmasoft», Russia), 5 mL of the solution 
intravenously. Patients in Group 2 were received 
once a day 40 mg of 3-hydroxy-6-methyl-2-
ethylpyridine (Emoksipin, endocrine Plant, Moscow, 
Russia) as a 4% solution of 1 ml intramuscularly and 
1000 mg of 2-oxo-1 pyrrolidine-acetamide 
(Piracetam, Borisov factory, Belarus) in the form of 5 
ml of 20% solution intravenously. In the 3rd group it 
was once daily administered 200 mg aktovegina 
(Aktovegin, «Nycomed Austria GmbH», Austria) in 
a 5 mL containing 200 mg aktovegina, intravenously 
and 1000 mg of choline alfostserata (Cereton, «Sotex 
FarmFirma», Russia) intravenously in 200.0 ml of 
0.9% sodium chloride solution. 
Treatment was in line with the principles of 
evidence-based medicine. All the patients were on 
the nitrate-free diet. 
Laboratory assessment. To determine the 
laboratory parameters of blood from the cubital vein 
was taken in the morning on an empty stomach, in 
the first day of admission and before discharge on the 
14th day in a volume of 10 ml. 
In making an assessment of haemogram it has 
been based upon the physiological norm, 
corresponding to the international system of units in 
clinical investigations. 
Determination of levels of TNF, IL-1β, IL-6, IL-
8, IL-18, IL-4, IL-10 receptor antagonist IL-1 (IL-1 
Ra), INFγ, IL-2, IL-17, complement components ( 
C3, C3a, C4, C5, C5a), its inhibitors (factor H, C1-
inhibitor), immunoglobulin class M, G, A (IgM, G, 
A), ceruloplasmin, and neopterin C-reactive protein 
was performed with the help of commercial panel of 
immunoferment analysis with detection of the 
products in the wavelength range 405-630 nm. C1 
inhibitor concentration was determined by a 
chromogenic method ability to inhibit C1 esterase. 
The intensity of the LPO processes were 
evaluated by conventional methods on the content in 
the blood plasma polyunsaturated fatty acid 
degradation products - derivatives of thiobarbituric 
acid (MDA and AGP). Сatalase activity was 
determined [19] and superoxide dismutase [18]. Total 
plasma antioxidant activity was determined by a 
method of inhibition of the oxidation of ascorbate 
and ferroevoke corrosion Tween-80 and MDA. 
Absorbance was measured at 532 nm after 48 hours 
of incubation at 40 ° C. The content of the stable 
metabolite of nitric oxide in the blood plasma was 
determined spectrophotometrically using the Griess 
reagent and detection appeared products at a 
wavelength of 540 nm. The results were calculated 
by standard curve using solutions of sodium nitrite. 
Analysis of clinical and laboratory results were 
carried out before and 2 weeks after the complex 
treatment of patients prior to discharge from office. 
The results of clinical, neuropsychological and 
laboratory tests were compared immune to the 
dynamics of treatment and with the same results it 
was in the active group. 
Statistical analysis of the results. The clinical 
efficacy of the treatment was evaluated in points. The 
basis of the developed evaluation system is based on 
a retrospective analysis of 545 case histories of 
patients diagnosed with DEP, were hospitalized from 
2009 to 2014 to assign points methodology consistent 
diagnostic procedure has been used for one to three a 
certain set of symptoms, which is based on sequential 
analysis method proposed by Wald. Clinical signs for 
building predictive tables were selected for the task. 
Then, for each criterion it was calculated probability 
of occurrence, and then calculate the smoothed 
particular characteristics in each of the studied 
sample population [19]. These values allow to 
calculate for each characteristic diagnostic factors 
and calculate the information content of each of the 
signs. Naturally there was another screening of non-
informative features. In addition, for each chosen 
informative gradation characteristic of an indicator 
into three groups so as to equalize the diagnostic 
value of each indicator. 
Statistical processing of the studying results was 
conducted according to generally accepted criteria 
variational-statistical analysis with the calculation of 
the average values (M), an error arithmetic mean (m) 
using the Microsoft Excel software package, 2010. 
Significant differences were evaluated by U-test. 
Correlation analysis was performed using Spearman's 
rank correlation coefficient. Differences were 
considered statistically significant with p = 0,05. 
For immunological parameters were calculated 
ratio diagnostic value, determined by the formula of 
disorders of the immune system by selecting from all 
the studied parameters of the top three most 
distinguished level of standards expected level of 
immune disorders, ranking algorithm largest extent 
disorders conducted a correlation analysis between 
immune parameters and clinical results, calculates the 
sum of degrees of correction for each treatment 
regimen [20]. 
RESULTS OF RESEARCH 
Changes in the immune and metabolic 
parameters in vascular encephalopathy affected by 
hypertensive disease. Indicators DEP patients with 
stage II affected by  hypertensive disease in the target 
groups to treat each other don’t differ. It was 
evaluated average, determined by the total in three 
groups. Prior to treatment in the patients’ plasma 
DEP II stage essential hypertension found a 
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significant increase in the concentration of cytokines 
INFγ, IL-2, IL-17, anti-inflammatory (TNF, IL-1β, 
IL-6, IL-8, IL-18) with simultaneous increase of anti-
inflammatory IL-4 and IL-10, with unchanged 
content IL-1 Ra (fig. 1). 
The detected increase in C5, C5a, reduction of C3 
and C4 components of the complement system and all 
studied classes of immunoglobulins (IgM, IgG, IgA) 
in unmodified concentration, compared to donors, 
inhibitors of the complement system (factor H, C1-
inhibitor ) and C3a component (fig. 1). 
 
Designations: 
1 - the radius of the circle marked in the controls; 
2 -  - DEP indicators of patients with 
stage II affected by hypertensive disease; 
3 -  - p> 0.05, the rate of patients with stage 
II DEP affected by hypertensive disease isn’t different 
from the comparison group. 
Figure 1. Changes in immune parameters in patients with 
discirculatory encephalopathy stage II affected by 
hypertensive disease before treatment. 
 
The blood plasma of patients DEP stage II 
found an increase in the concentration of the 
intermediate and final products of lipid peroxidation 
(MDA AGP) concentration SMNO and CRP, a 
significant change in the antioxidant defense 
indicators (reduction of catalase activity, TAA serum 
CP level, increase of neopterin). 
Pharmacological rehabilitation of patients 
with discirculatory encephalopathy against the 
background of essential hypertension drug 
combination with nootropic and antioxidant 
properties. Introduction to the treatment regimen of 
patients with DEP stage II affected by hypertensive 
disease cerebrolysin and mexidol normalized levels 
of C3, C4 complement components and of IgG, to 
reduce the concentration of TNF, IL-1.beta, IL-6, IL-
8, IL-18, IFγ, IL-2, IL-17 C5 complement component, 
increased IgA content (but not to the level of 
provisions recorded in the comparison group) 
increased in comparison with the moment of 
admission to the clinic, the content of anti-
inflammatory cytokines IL-10 and IL-1 Ra (table 1). 
When using emoxipine and piracetam and the 
normalization of levels of IL-17, C3, and C4 
components of complement, and IgG, correction 
(change in direction, but not up to the level of 
control) content of TNF, IL-1β, IL-6, IL-8, IL 18, 
INFγ, IL-2, C5, C5a complement components, IgA 
and M, increasing the concentration of anti-
inflammatory cytokines IL-4, IL-10 and IL-1 Ra, 
complement regulators (C1-inhibitor and factor H) 
compared with the original results (table 1). 
The combination of an aktovegin and cereton 
was the most effective as normalized the content in 
plasma of IL-1β, IL-6, IL-2, IL-17, C3, C4-
components of a complement, IgG, more on to 
comparison with other schemes, correction 
concentration C5a-component of a complement, IgM 
and I increased the level of anti-inflammatory 
cytokine (IL-4, IL-10), IL-1 Ra, complement 
regulators (C1-inhibitor and factor H) (table 1). 
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Table 1 
Change in the concentration of cytokines and complement system components in patients with stage II DEP affected by hypertensive disease in the application  
of neuroprotective combinations and antioxidant drugs (M±m; n=48) 
 
Indicators 
Units 
measurement
s 
1 2 3 4 5 
Control group 
Patients with DEP stage II 
Before treatment 
Cerebrolysin and  
Mexidol 
Emoxipine and Piracetam 
Aktovegin and 
Cereton 
TNF pg/ml 0,5±0,07 20,23±0,91*1 10,12±1,05*1,2 9,07±0,46*1,2 9,1±0,53*1,2 
IL-1β pg/ml 1,6±0,09 11,79±0,84*1 6,22±0,43*1,2 6,26±0,48*1,2 1,29±0,14*2-4 
IL-6 pg/ml 1,9±0,05 17,2±1,08*1 5,32±0,51*1,2 4,06±0,41*1-3 2,34±0,42*2-4 
IL-8 pg/ml 2,0±0,11 26,38±1,88*1 6,39±0,58*1,2 5,76±0,94*1,2 7,0±0,55*1,2 
IL-18 pg/ml 50,1±2,3 1539,4±137,1*1 677,5±38,4*1,2 288,1±20,1*1-3 610,4±66,3*1,2,4 
IL-4 pg/ml 0,3±0,02 7,53±0,67*1 6,4±0,41*1 11,76±0,62*1-3 11,18±0,68*1-3 
IL-10 pg/ml 2,5±0,08 3,07±0,2*1 11,56±0,54*1,2 12,98±0,51*1,2 13,47±0,41*1,2 
IL-1 Ra pg/ml 131,4±12,7 142,7±13,5 159,2±10,1*1 200,3±21,8*1-3 197,2±10,7*1-3 
IFγ pg/ml 0,3±0,01 288,94±1,54*1 65,12±3,76*1,2 45,65±3,57*1-3 68,84±8,5*1,2,4 
IL-2 pg/ml 0,2±0,03 12,54±0,31*1 6,64±0,43*1,2 1,5±0,09*1-3 1,81±0,12*1-3 
IL-17 pg/ml 6,31±0,8 24,65±1,95*1 10,75±1,25*1,2 5,58±0,42*2,3 5,54±0,5*2,3 
С3 mg/dl 127,9±4,68 119,92±2,83
*1
 133,83±3,64*2 135,5±3,32*2 135,4±2,9*2 
С3а ng/ml 49,4±5,6 44,2±2,7 50,6±6,07 47,9±5,54 45,13±5,09 
С4 mg/dl 25,8±2,52 20,78±0,96
*1
 26,92±1,29*2 28,1±1,05*2 27,0±1,34*2 
С5 ng/ml 108,6±9,1 200,3±10,1
*1
 174,2±8,91*1,2 131,2±10,3*1-3 144,3±8,0*1-3 
С5а ng/ml 81,8±5,24 133,4±6,2
*1
 124,8±5,5*1 100,6±8,82*1-3 98,3±4,7*1-3 
С1-inh. ng/ml 386,3±17,9 391,5±20,4 407,8±18,1 587,2±48,8
*1-3
 713,4±61,2*1-4 
Factor Н ng/ml 38,1±8,3 42,3±6,33 44,5±5,3 62,7±7,1*1-3 68,16±7,9*1-3 
IgM mg/dl 80,8±4,8 9,69±1,42*1 8,33±0,51*1 12,36±0,94*1-3 34,88±2,34*1-4 
IgG mg/dl 1284,6±39,2 1148,19±25,3*1 1222,0±31,1*2 1214,8±33,84*2 1352,5±55,34*2 
IgA mg/dl 44,9±6,8 3,61±0,31*1 25,9±2,31*1,2 23,13±2,33*1,2 26,99±1,5*1,2 
Note. In the table there are marked with an asterisk significant differences of arithmetic means (p = 0,05); figures marked with an asterisk beside are with respect to 
which group indexes are given to these differences. 
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Comparison efficiency of clinical and 
laboratory pharmacological correction of immune 
and oxidant disturbances in vascular 
encephalopathy affected by hypertension. On 
admission to hospital in patients with stage II DEP 
set change 25 of 30 (83.3%) there was established 
immune metabolic indicators indicating the presence 
of oxidative stress in patients, immune inflammation 
and endothelial dysfunction (table 2). 
Using combination therapy with combination of 
cerebrolysin meksidol was  normalized 6 (24%) and 
corrected, but not to the performance standards 13 
(52%) of the 25 modified before treatment the 
amount of immune and oxidative parameters. Using 
emoxipine and piracetam normalized 7 (28%) and 18 
to correct (72%), laboratory parameters. The most 
effective, according to the dynamics of change in the 
treatment of laboratory result, has a combination of 
aktovegin and cereton since the introduction of these 
products into the complex pharmacotherapy patients 
DEP stage II normalized 12 of 25 (48%) and to 
correct the 13 (52%) changed at the beginning of 
treatment immune parameters (table 2). 
Table 2  
Immune efficacy of combinations neuroprotective and antioxidant  
drugs in patients with DEP (M±m; n=48) 
№ Patient group 
Changed laboratory 
indicators before 
treatment 
Therefrom (%): 
Corrected Normalized Without changing 
1. Cerebrolysin +meksidol 
83,3% 
52,0 24,0 24,0 
2. Emoksipin +piracetam 72,0 28,0 0 
3. Aktovegin +cereton 52,0 48,0 0 
 
By proportion of the number of violations of lab 
values in patients with different pharmacotherapy 
with the division of powers of the depth disorders 
found that before treatment 25 out of 30 it studied 
indicators which were violated in varying degrees. 
Since level disturbances (LD) III it was 17 indicators 
with LD II - 3, and a LD I - 5, wherein the formula of 
disturbances (FD) were: IFγ+3, MDA
+
3, TNF
+
3. After 
the treatment, which included a combination of 
cerebrolysin and mexidol, the reduce of a number 
modified indicators was to 19, with a LD III turned 
10 indicators with LD II - 8, with the I LD - 1 and FD 
consisted of IFNγ+3, IL-2
+
3, TNF
+
3. 
After inclusion complex of emoxipine 
pharmacotherapy and piracetam there were 18 
disturbed indicators, it was 9 LD with III, II and I, 5 
and 4 score, FD was IFNγ+3, IL-4
+
3, TNF
+
3. The most 
effective was the use of a combination aktovegina 
and cereton since reduced the number of indicators 
broken to 13, while LD was 8 with the III, II and I, 
respectively 2 and 3. FD  comprised IFγ+3, IL-4
+
3, 
TNF
+
3. 
In accordance with the sum of the degrees of 
correction for each treatment regimen it was found 
that correction of Immune Parameters in Patients 
DEP stage II affected by hypertensive disease, a 
combination of aktovegina and cereton was more 
effective with as a sum of compensation levels for the 
scheme was 5540, with the combination emoxipine 
and piracetam amount correction degree was 3497, 
while the combined using of cerebrolysin and 
mexidol amount of compensation was 127 degrees. 
There was a coincidence when comparing the 
changes in the immune status and metabolic 
parameters under the influence of the various 
schemes of pharmacotherapy with clinical result. 
So, using сerebrolysin and mexidol reduced the 
mean scores of clinical symptoms with a 26,2 ± 0,9 
to 23,3 ± 0,7 (p = 0,05), and using emoxipine 
piracetam to 19,1 ± 1,7 (p = 0.05). There was a 
reduction decrease in egocentric symptoms of the 
disease as a result of treatment, evidence reduction of 
anisoreflexia, mend of cognitive function and 
emotional state of patients. 
The research results have shown the most 
maximal clinical efficacy has a therapeutic regimen 
including aktovegin and cereton, containing the 
number of points to 14,8 ± 1,0 (p = 0,01); in the 
treatment group it was showed a significant decrease 
in the intensity of complaints, a significant 
improvement in cognitive functions and emotional 
state of patients. 
Based on experience it can be concluded that the 
most effective treatment is the combination of DEP 
aktovegina with cereton. 
Through studies of laboratory correlations 
parameters, complaints and clinical syndromes in 
patients with discirculatory encephalopathy stage II 
affected by hypertensive disease there were positive 
things between the levels IL-6, IL-17 IFγ and 
intensity of headaches, dizziness, sonitus, shaky 
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walk, defective memory and attention, mood swings, 
vestibular ataxia, hereditary cerebellar ataxia, 
pseudobulbar syndrome, pyramid sign, 
psychopathological symptom. Negative significant 
correlations were established between these 
symptoms and syndromes and neopterin content, 
activity of catalase. 
Immune alterations are one of the stages of the 
ischemic cascade releaser hypoxia and it occurs of 
shifts ionic homeostasis, «the phenomenon of 
excitotoxicity», oxidative stress, which leads to the 
gradual degeneration and death of neurons [6, 21, 
22]. Patients with DEP stage II affected by 
hypertensive disease before treatment there were 
established signs of oxidative stress (elevated levels 
of lipid peroxidation products and stable metabolites 
of nitric oxide, a decrease of antioxidant protection 
factor) and immune inflammation which level was 
rising especially of pro-inflammatory cytokines, 
imbalances of components complement system, 
reduction of immunoglobulins. 
The combination of aktovegina cereton was 
effective in these circumstances because both 
activates cereton phosphatidylcholine synthesis - a 
major phospholipid membrane components, and 
stimulates the release of acetylcholine, - 
neurotransmitter synaptic transmission provides 
enhances metabolic processes and improves blood 
flow in the central nervous system. Aktovegin is an 
effective antioxidant and antihypoxant, it’s also 
hemoderivative obtained by dialysis and 
ultrafiltration. Antioxidant effect of aktovegina is 
determining its neuroprotective effects, manifested in 
the reduction of reactive oxygen species, and this 
effect is dose-dependent. It has insulinoid effects of 
the drug, also a positive effect on the glucose 
transport and utilization, we cannot entirely possible 
that there are the presence of neurotrophic and 
anabolic effects on the central nervous system. Most 
of the drug's effectiveness is related to the rate of 
realization of its biological effects. More pronounced 
immune metabolic effects can be explained as a 
direct effect on the cells of the immune system by 
these pharmacodynamic effects caused by a decrease 
in the number of oxygen free radicals and reducing 
cellular antioxidant status systems [16, 23]. 
In a less degree a combination of piracetam and 
emoxipine was incompetent. Piracetam is a 
metabolite with strong nootropic effects and a 
complex membrane-stabilizing action emoksipin has 
antioxidant, antihypoxant properties, 
vasculoprotective and antiplatelet therapy. Probably 
these effects are not enough for complete relief of 
ischemic and oxidative processes in the brain to 
normalize capillary endothelial function and energy 
processes in neurocytes. 
The least effective was a combination of 
cerebrolysin and mexidol in the correction of immune 
and metabolic disorders with DEP, although the 
derivatives of 3-hydroxypyridine have marked 
antioxidant activity. We can assume that 
cerebrolysin, which provides metabolic regulation, 
neuroprotection, functional neuromodulation and 
neurotrophic activity in hypoxic conditions influence 
in less extent on pathogenetic mechanisms of DEP in 
comparison with piracetam and cereton [24, 25]. 
Suggests that effective approaches will be using L-
arginine and arginase inhibitors [26, 27, 28]. 
So, based on the dynamics of immunological 
and oxidative parameters and regression of clinical 
symptoms of the disease can be argued that the 
degree of reducing the effectiveness of the 
investigated combination of medications nootropic 
and antioxidant action when DEP stage II affected by 
hypertensive disease are located in the following 
order: complex pharmacotherapy, including 
aktovegin with cereton → emoksipin with piracetam 
→ cerebrolysin with meksidol. 
DEP triggers to neurological deficits, cognitive 
disorders, threatens the development of stroke. Early 
treatment can save the professional, social and 
personal adaptation of the patient for many years, it 
improves the prognostication to the duration of the 
patient's life. 
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